Acute Migraine Treatment to Rely on Improved Intranasal Migraine Drugs Discovery for Future Expansion: Fact.MR

18 May 2021
Fast TrackAcquisition
Leading players are focusing on introducing novel treatment through research & development to deliver improved results for the patients with acute migraine Award winning market research company Fact.MR’s ongoing research study on global intranasal migraine drugs market studies the market for the forecast period of 2021 and 2031. Rising cases of acute and chronic headache among the young-adult population is expected to increase the adoption of intranasal migraine drugs. Expansion in research and development activities for the development of novel treatments to provide quick relief for the cerebral and sinus pain will provide growth opportunities for the key players in the coming years. According to Fact.MR, the market is expected to showcase a positive growth over the forecast period backed by the rising demand of intranasal migraine drugs from hospital & retail pharmacies. As per the analysis, around 95% of patients with migraine issues prefer the intranasal migraine drugs. Request a report sample to gain comprehensive insights at There are some side-effects recorded such as quick heartbeat, muscle torment in legs/arms, and serious/moderate stomach torment that may hamper the demand. However, ongoing research & development (R&D) activities for the improvement of intranasal migraine drugs by manufacturers will overcome the constraints of the market. Hence, key players are investing heavily for the development of improved intranasal migraine drugs for the treatment of acute & chronic migraine. Thereby, bolstering the growth. “Increasing R&D activities, new product launches by key manufacturers, and fast track drug approvals by regulatory bodies such as the U.S. Food and Drug Administration for acute and chronic migraine are expected to provide lucrative opportunities in the upcoming decade,” says the Fact.MR analyst. Key Takeaways Increasing cases of acute migraine are anticipated to spur the sales of intranasal migraine drugs Hospital & retail pharmacies are anticipated to be the primary end-users for intranasal migraine drugs market In terms of therapeutic class, opioids and antihistamines are expected to lead the segment throughout the forecast period United States is anticipated to spearhead the Intranasal migraine drugs market growth in North America UK will lead the second largest European Intranasal migraine drugs market through 2021 Prominent Drivers Growing cases of chronic sinusitis are expected to accelerate the demand for Intranasal migraine drugs Technological advancements in the healthcare industry for intranasal migraine drugs are expected to boost the market growth Key Restraints Lack of awareness for the alternative treatment for lung contaminations is likely to pose a challenge for the intranasal migraine drugs manufacturers Side effects associated with the drugs such as shortness of breath, quick heartbeat and more will act as a restraint for the market Discover more about the intranasal migraine drugs market with figures, data tables and the table of contents. Competitive Landscape Key players listed by Fact.MR operating in global intranasal migraine drugs market includes Aegis Therapeutics LLC, Neuro Pharma, Rd. Reddy’s Laboratories, Novartis AG, Pfizer Inc., Lockhart LTD, Roche, Sanofi, Merck, Baxter International Inc., Becton, Dickinson & Company, GlaxoSmithKline PLC and Johnson & Johnson among others. Product launches and expansion of portfolio along with strategic mergers & acquisition remains the core strategies for the aforementioned players to gain a competitive edge in the industry. For instance, on January 20th 2021, Impel Neuro Pharma received the approval from U.S. Food and Drug Administration (FDA) for the new drug application for INP104, for the acute treatment of migraine headaches with or without aura in adults to deliver a lower dose of dihydroergotamine mesylate to the upper nasal state. Also, on 2nd March 2021, Cipla received U.S FDA approval for nasal spray for treating migraine attacks/ Furthermore, in June 2020, Tonix Pharmaceuticals announced the acquisition of non-addictive migraine and pain treatment programs of Trigemina Inc. and will acquire the license of TNX-1900 intranasal oxytocin has the potential to treat migraine and craniofacial pain. Get Customization on this Report for Specific Research Solutions More Insights on the Intranasal Migraine Drugs Market Fact.MR sheds an in-depth analysis on global intranasal migraine drugs market over the forecast period of 2021 and 2031. In order to understand the market perspective, trends and challenges, the market is segmented on the basis of therapeutic class (corticosteroids, NSAID’s, opioids, antibiotics, local anesthesia, and antihistamines), indication (common migraine, classic migraine, cluster migraine, and others), range (chronic and acute), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and third party manufacturing companies), and regions (North America, Latin America, Europe, CIS & Russia, Asia Pacific excluding Japan, Japan and Middle East & Africa). Explore Fact.MR’s Coverage on the Healthcare Domain Digital Migraine Treatment Device Market: A recent study by Fact.MR on the digital migraine treatment device market offers an unbiased analysis on the opportunities and trends through 2021 and beyond. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the challenges, restraints, and opportunities for key market players along with key stakeholders and emerging players. High Flow Nasal Cannula Market: Fact.MR gives a detailed assessment of High flow nasal cannula market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study. Preclinical Brain Imaging Market: Fact.MR delivers an in-depth analysis on global preclinical brain imaging market with the strategies and competitive landscape through 2021 and beyond. The key players’ market share data provided by the report given you a detailed insights on the shortcomings and forthcomings of the market for the forecast period. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: Follow Us: LinkedIn | Twitter Source: Fact.MR
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.